Literature DB >> 19363593

The actuarial survival analysis of the surgical and non-surgical therapy regimen for chronic thromboembolic pulmonary hypertension.

Hui-Li Gan1, Jian-Qun Zhang, Ping Bo, Qi-Wen Zhou, Sheng-Xun Wang.   

Abstract

AIM: To characterize the in-hospital mortality and the actuarial survival of surgical and non-surgical therapy regimen in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
METHODS: A retrospective cohort study was conducted in 504 patients with CTEPH, who were treated surgically (n = 360), or non-surgically (n = 144) in Anzhen Hospital from February 1989 to August 2007. The patients in surgical group received a standard pulmonary thromboendarterectomy (PTE), while those in non-surgical group were given thrombolytic therapy. The actuarial survival of the two groups was determined with the Kaplan-Meier survival curves. Univariate analysis and multivariate binary logistic regression and Cox proportional hazard analysis were used to identify the risk factors for the in-hospital and late deaths.
RESULTS: The in-hospital mortality for the surgical group and non-surgical group were 4.44% and 3.50%, respectively. For the proximal type of CTEPH, the actuarial survival at 10 and 15 years of the surgical group and non-surgical group were 94.60 +/- 2.38%, 90.96 +/- 4.24% and 81.4 +/- 7.14%, 56.43 +/- 14.7%, respectively (chi(2) = 12.33, P = 0.0004). For the distal type of CTEPH, the actuarial survival at 10 and 15 years of the surgical group and non-surgical group were 71.78 +/- 4.66%, 29.57 +/- 15.1% and 69.84 +/- 7.78%, 32.59 +/- 13.7%, respectively (chi(2) = 0.03, P = 0.874).
CONCLUSION: The PTE procedure has statistically superiority over thrombolytic therapy for the proximal type of CTEPH in terms of actuarial survival; however, for the distal type of CTEPH, the PTE procedure provides no benefits with regard to actuarial survival.

Entities:  

Mesh:

Year:  2009        PMID: 19363593     DOI: 10.1007/s11239-009-0319-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  23 in total

1.  Reflections on wave reflections in chronic thromboembolic pulmonary hypertension.

Authors:  Robert Naeije; Sandrine Huez
Journal:  Eur Heart J       Date:  2007-03-23       Impact factor: 29.983

Review 2.  Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.

Authors:  Paul Bresser; Joanna Pepke-Zaba; Xavier Jaïs; Marc Humbert; Marius M Hoeper
Journal:  Proc Am Thorac Soc       Date:  2006-09

3.  The clinical course of patients with suspected pulmonary embolism.

Authors:  E J van Beek; P M Kuijer; H R Büller; D P Brandjes; P M Bossuyt; J W ten Cate
Journal:  Arch Intern Med       Date:  1997 Dec 8-22

4.  Results of one-year anticoagulation in patients with newly detected chronic thromboembolic pulmonary hypertension not treated with pulmonary endarterectomy.

Authors:  Renata Romaszkiewicz; Jerzy Lewczuk; Piotr Piszko; Jacek Jagas; Lucyna Lenartowska; Bartosz Ludwik; Wiesława Sawa; Krzysztof Wrabec
Journal:  Kardiol Pol       Date:  2006-11       Impact factor: 3.108

5.  The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study.

Authors:  R J Hughes; X Jais; D Bonderman; J Suntharalingam; M Humbert; I Lang; G Simonneau; J Pepke-Zaba
Journal:  Eur Respir J       Date:  2006-04-12       Impact factor: 16.671

6.  Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).

Authors:  Silvia Ulrich; Rudolf Speich; Guido Domenighetti; Thomas Geiser; John-David Aubert; Thierry Rochat; Lars Huber; Ursula Treder; Mannuel Fischler
Journal:  Swiss Med Wkly       Date:  2007-10-20       Impact factor: 2.193

7.  Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension.

Authors:  Robin Condliffe; David G Kiely; J Simon R Gibbs; Paul A Corris; Andrew J Peacock; David P Jenkins; Denise Hodgkins; Kim Goldsmith; Rodney J Hughes; Karen Sheares; Steven S L Tsui; Iain J Armstrong; Chantal Torpy; Rachel Crackett; Christopher M Carlin; Clare Das; J Gerry Coghlan; Joanna Pepke-Zaba
Journal:  Am J Respir Crit Care Med       Date:  2008-02-21       Impact factor: 21.405

8.  Predictors of outcome in chronic thromboembolic pulmonary hypertension.

Authors:  Diana Bonderman; Nika Skoro-Sajer; Johannes Jakowitsch; Christopher Adlbrecht; Daniela Dunkler; Sharokh Taghavi; Walter Klepetko; Meinhard Kneussl; Irene M Lang
Journal:  Circulation       Date:  2007-04-09       Impact factor: 29.690

9.  A novel echocardiographic predictor of in-hospital mortality and mid-term haemodynamic improvement after pulmonary endarterectomy for chronic thrombo-embolic pulmonary hypertension.

Authors:  Maxim Hardziyenka; Herre J Reesink; Berto J Bouma; H A C M Rianne de Bruin-Bon; Maria E Campian; Michael W T Tanck; Renée B A van den Brink; Jaap J Kloek; Hanno L Tan; Paul Bresser
Journal:  Eur Heart J       Date:  2007-03-06       Impact factor: 29.983

10.  Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension.

Authors:  Jay Suntharalingam; Rajiv D Machado; Linda D Sharples; Mark R Toshner; Karen K Sheares; Rodney J Hughes; David P Jenkins; Richard C Trembath; Nicholas W Morrell; Joanna Pepke-Zaba
Journal:  Thorax       Date:  2007-02-07       Impact factor: 9.139

View more
  5 in total

1.  Chronic Thromboembolic Pulmonary Hypertension: A Worldwide View of How Far We Have Come.

Authors:  Wassim H Fares; Gustavo A Heresi
Journal:  Lung       Date:  2016-02-29       Impact factor: 2.584

2.  Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review.

Authors:  John D L Brookes; Crystal Li; Sally T W Chung; Elizabeth M Brookes; Michael L Williams; Nicholas McNamara; Sofia Martin-Suarez; Antonio Loforte
Journal:  Ann Cardiothorac Surg       Date:  2022-03

3.  Chronic Thromboembolic Pulmonary Hypertension: Experience from a Single Center in Mexico.

Authors:  Nadine Al-Naamani; Gaudalupe Espitia H; Hugo Velazquez-Moreno; Benjamin Macuil-Chazaro; Arturo Serrano-Lopez; Ricardo S Vega-Barrientos; Nicholas S Hill; Ioana R Preston
Journal:  Lung       Date:  2016-01-09       Impact factor: 2.584

4.  Inflammatory response and pneumocyte apoptosis during lung ischemia-reperfusion injury in an experimental pulmonary thromboembolism model.

Authors:  Chaosheng Deng; Zhenguo Zhai; Dawen Wu; Qichang Lin; Yuanhua Yang; Minxia Yang; Haibo Ding; Xiaoming Cao; Qiaoxian Zhang; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

5.  Beneficial effects of inhaled NO on apoptotic pneumocytes in pulmonary thromboembolism model.

Authors:  Chaosheng Deng; Minxia Yang; Qichang Lin; Yuanhua Yang; Zhenguo Zhai; Kaixiong Liu; Haibo Ding; Xiaoming Cao; Zhihua Huang; Lina Zhang; Jianming Zhao
Journal:  Theor Biol Med Model       Date:  2014-08-10       Impact factor: 2.432

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.